Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Not Recruiting

Trial ID: NCT01856192


This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide work in treating patients with newly diagnosed stage II-IV diffuse large B cell lymphoma. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether rituximab and combination chemotherapy are more effective when given with or without lenalidomide in treating patients with diffuse large B cell lymphoma.

Official Title

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma

Stanford Investigator(s)

Ranjana Advani
Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma


Inclusion Criteria:


   - Histologically confirmed DLBCL expressing CD20 antigen; patients with transformed
   lymphoma are excluded; in this regard, patients with composite lymphoma in the
   diagnostic tissue (concomitant DLBCL and follicular or other low-grade lymphoma
   component) are excluded; however, patients with DLBCL in primary diagnostic tissue but
   a bone marrow that shows low grade or indeterminate lymphoma are eligible; patients
   with known primary mediastinal large B-cell lymphoma (PMLBCL) are excluded; similarly,
   patients with known c-myc translocation (by fluorescence in situ hybridization)
   positive DLBCL are encouraged to participate in trials specifically designed for these
   patients; however patients with known c-myc DLBC positive are NOT excluded from this
   study; c-myc testing prior to study enrollment is NOT required

   - Stages II bulky disease (defined as mass size of more than 10 cm), stage III, or IV
   (Ann Arbor staging); patients with stage I and stage II non-bulky disease are excluded
   from this study

   - A paraffin-embedded tumor tissue specimen from the initial diagnostic biopsy has been
   located and ready to ship to the Mayo Clinic Lymphoma Laboratory following
   pre-registration; Note: excisional tumor biopsy is preferred; core needle biopsies
   will be considered adequate if there is enough tissue for the mandatory central
   pathology review immunohistochemistry and Genomics Education Partnership (GEP);
   submission of a tumor block is preferred, but if unavailable submit alternative

   - Eastern Cooperative Oncology Group (ECOG) performance status 0-2

   - Previously untreated and not receiving any other agent that would be considered as a
   treatment for the lymphoma; for subjects with severe systemic symptoms, compressive
   disease, or rapidly progressing symptomatic adenopathy, are allowed for lymphoma
   associated symptom treatment with up to 1 mg/kg/day prednisone, or equivalent, for a
   maximum of 7 days is permitted prior to beginning the treatment, at the discretion of
   the investigator; a washout period does not apply

   - No known central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with
   malignant lymphoma cells; these patients are usually treated with CNS directed
   therapy; screening for cerebrospinal fluid (CSF)/CNS involvement is NOT required but
   can be performed per treating medical doctor (MD) discretion; intrathecal (IT)
   methotrexate or IT cytarabine prophylaxis in patients with negative CSF who are felt
   to be at high risk of CNS relapse is allowed per local MD discretion; this should be
   noted on the treatment form

   - Absence of history of myocardial infarction =< 6 months, or congestive heart failure
   requiring use of ongoing maintenance therapy for life-threatening ventricular

   - Absence of history of deep venous thrombosis/embolism, threatening thromboembolism or
   known thrombophilia; patients with a history of deep vein thrombosis(DVT)/pulmonary
   embolism (PE) or thrombophilia may participate if they are willing to be on full
   anticoagulation during the treatment if randomized to rituximab, cyclophosphamide,
   doxorubicin hydrochloride, vincristine sulfate, and prednisone (R2CHOP) arm A; full
   anticoagulation is defined as warfarin, factor X inhibitors, or low molecular weight
   heparin at therapeutic doses

   - Patient must be able and willing to receive anticoagulation therapy with aspirin
   70-325 mg daily prophylaxis, low molecular weight heparin, factor X inhibitors or
   warfarin; patients unable or unwilling to take any prophylaxis are NOT eligible

   - Absence of history of acquired immune deficiency syndrome (AIDS)-related conditions
   (other than the presenting DLBCL) or post-transplant lymphoproliferative disorder
   (PTLD) in immunocompromised patients; patients with human immunodeficiency virus (HIV)
   on antiretroviral therapy other than zidovudine (AZT) and/or stavudine and without
   prior AIDS defining conditions and adequate CD4 count (> 400) are eligible

   - No other active malignancy requiring therapy such as radiation, chemotherapy, or
   immunotherapy; exceptions to this are as follows: localized non-melanotic skin cancer
   and any cancer that in the judgment of the investigator has been treated with curative
   intent and will not interfere with the study treatment plan and response assessment

   - No history of radiation therapy to >= 25% of the bone marrow for other diseases or
   history of anthracycline therapy

   - Patients must not be receiving erythroid stimulating agents (EPO: Procrit, Aranesp)


   - Patient meets the eligibility criteria outlined above

   - Site has received notification from Mayo Clinic - Rochester Division of
   Hematopathology of the central confirmation of diagnosis and tissue adequacy for
   mandatory research studies

   - Patients must have measurable disease (at least 1 lesion of >= 1.5 cm in one diameter)
   as detected by computed tomography (CT) or the CT images of the positron emission
   tomography (PET)/CT

   - International Prognostic Index (IPI) of 2 or greater

   - Ejection fraction of >= 45% by either multi-gated acquisition (MUGA) scan or
   echocardiogram (ECHO)

   - Absence of co-morbid systemic illnesses or other severe concurrent disease which, in
   the judgment of the investigator, would make the patient inappropriate for entry into
   this study or interfere significantly with the proper assessment of safety and
   toxicity of the prescribed regimens, including, but not limited to, ongoing or active
   infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements

   - Absolute neutrophil count (ANC) >= 1500

   - Platelets (PLT) >= 100,000

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) or if total bilirubin is > 1.5 x
   ULN, the direct bilirubin must be normal

   - Alkaline (Alk.) phosphatase =< 3 x ULN unless evidence of the direct liver involvement
   by lymphoma - then =< 5 x ULN

   - Aspartate aminotransferase (AST) =< 3 x ULN unless evidence of the direct liver
   involvement by lymphoma - then =< 5 x ULN

   - Creatinine =< 2 x ULN or creatinine clearance (CrCl) > 30 ml/min

   - Women must not be pregnant or breast-feeding

   - Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
   test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to and again
   within 24 hours of starting lenalidomide and must either commit to continued
   abstinence from heterosexual intercourse or begin TWO acceptable methods of birth
   control, one highly effective method and one additional effective method AT THE SAME
   TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to
   ongoing pregnancy testing; a female of childbearing potential is any woman, regardless
   of sexual orientation or whether they have undergone tubal ligation, who meets the
   following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or
   2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has
   had menses at any time in the preceding 24 consecutive months)

   - Men must agree to use a latex condom during sexual contact with a FCBP even if they
   have had a successful vasectomy; all patients must be counseled at a minimum of every
   28 days about pregnancy precautions and risks of fetal exposure


drug: Prednisone

biological: Rituximab

drug: Cyclophosphamide

drug: Lenalidomide

drug: Doxorubicin Hydrochloride

other: Laboratory Biomarker Analysis

drug: Vincristine Sulfate

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

Stanford Cancer Center South Bay
2589 Samaritan Drive
San Jose, CA 95124

New Trial Alerts